Recce Pharmaceuticals (ASX:RCE) achieves 5,000 weekly doses of RECCE 327 under GMP
Recce Pharmaceuticals achieved a production of 5,000 doses per week of RECCE 327 under Good Manufacturing Practices.
The milestone supports ongoing clinical trials, including Phase 1 Phase 2, and upcoming Phase 3 trials, meeting regulatory standards such as those set by the US Food and Drug Administration.
The production achievement underscores Recce's commitment to delivering R327 to patients and advancing towards investigational new drug submission.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
